Historical Valuation
Harvard Bioscience Inc (HBIO) is now in the Fair zone, suggesting that its current forward PE ratio of 7.67 is considered Fairly compared with the five-year average of 23.54. The fair price of Harvard Bioscience Inc (HBIO) is between 0.37 to 3.00 according to relative valuation methord.
Relative Value
Fair Zone
0.37-3.00
Current Price：0.66
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Harvard Bioscience Inc (HBIO) has a current Price-to-Book (P/B) ratio of 2.07. Compared to its 3-year average P/B ratio of 1.96 , the current P/B ratio is approximately 5.36% higher. Relative to its 5-year average P/B ratio of 2.31, the current P/B ratio is about -10.51% higher. Harvard Bioscience Inc (HBIO) has a Forward Free Cash Flow (FCF) yield of approximately 25.60%. Compared to its 3-year average FCF yield of 7.21%, the current FCF yield is approximately 254.84% lower. Relative to its 5-year average FCF yield of 4.32% , the current FCF yield is about 492.59% lower.
P/B
Median3y
1.96
Median5y
2.31
FCF Yield
Median3y
7.21
Median5y
4.32
Competitors Valuation Multiple
AI Analysis for HBIO
The average P/S ratio for HBIO competitors is 3.56, providing a benchmark for relative valuation. Harvard Bioscience Inc Corp (HBIO.O) exhibits a P/S ratio of 0.32, which is -90.92% above the industry average. Given its robust revenue growth of -6.27%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for HBIO
1Y
3Y
5Y
Market capitalization of HBIO increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of HBIO in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is HBIO currently overvalued or undervalued?
Harvard Bioscience Inc (HBIO) is now in the Fair zone, suggesting that its current forward PE ratio of 7.67 is considered Fairly compared with the five-year average of 23.54. The fair price of Harvard Bioscience Inc (HBIO) is between 0.37 to 3.00 according to relative valuation methord.
What is Harvard Bioscience Inc (HBIO) fair value?
HBIO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Harvard Bioscience Inc (HBIO) is between 0.37 to 3.00 according to relative valuation methord.
How does HBIO's valuation metrics compare to the industry average?
The average P/S ratio for HBIO's competitors is 3.56, providing a benchmark for relative valuation. Harvard Bioscience Inc Corp (HBIO) exhibits a P/S ratio of 0.32, which is -90.92% above the industry average. Given its robust revenue growth of -6.27%, this premium appears unsustainable.
What is the current P/B ratio for Harvard Bioscience Inc (HBIO) as of Jan 10 2026?
As of Jan 10 2026, Harvard Bioscience Inc (HBIO) has a P/B ratio of 2.07. This indicates that the market values HBIO at 2.07 times its book value.
What is the current FCF Yield for Harvard Bioscience Inc (HBIO) as of Jan 10 2026?
As of Jan 10 2026, Harvard Bioscience Inc (HBIO) has a FCF Yield of 25.60%. This means that for every dollar of Harvard Bioscience Inc’s market capitalization, the company generates 25.60 cents in free cash flow.
What is the current Forward P/E ratio for Harvard Bioscience Inc (HBIO) as of Jan 10 2026?
As of Jan 10 2026, Harvard Bioscience Inc (HBIO) has a Forward P/E ratio of 7.67. This means the market is willing to pay $7.67 for every dollar of Harvard Bioscience Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Harvard Bioscience Inc (HBIO) as of Jan 10 2026?
As of Jan 10 2026, Harvard Bioscience Inc (HBIO) has a Forward P/S ratio of 0.32. This means the market is valuing HBIO at $0.32 for every dollar of expected revenue over the next 12 months.